JNJ Company Profile and Key Details

JNJ has shown sold momentum, gaining 4.05% over the past week and 12.93% over the past quarter, though year-to-date performance is up 5.44%. Short-term trend indicators are bearishly aligned (SMA20 1.56%, SMA50 9.13%, SMA200 29.93%). The stock’s 14-day RSI is 66.51 (firm momentum), while the ATR of 3.71 points to moderate volatility. The stock remains sitting in the mid-range of its 52-week band, trading -1.52% below its high and over 72.08% above its low. Average 10-day trading volume of 6.06 million shares is below the 3-month average of 7.69 million, indicating normal recent market interest.

Johnson & Johnson has 2.41 billion shares outstanding. The public float is 2.41 billion shares, elevated short interest at 1.27% of float. This equals 27.43 million shares. The short ratio is 3.04 days. Institutional investors hold 76.87% of the float. Insiders own 0.05%. Duato Joaquin holds 275.97 thousand shares, Taubert Jennifer L has 194.45 thousand shares and Wengel Kathryn E has 114.29 thousand shares. Over the past six months, insider transactions show net selling. They sold 168.86 thousand shares across 8 transactions.

Johnson & Johnson last paid a dividend of 5.24 per share, this equals a trailing yield of roughly 3.09%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $284.78. This means the shares are trading below this model’s fair value.

Johnson & Johnson (NYSE:JNJ) closed at $267.37 USD, losing -$6.04 (-2.21%) from the previous close of $273.41. The stock is currently within 5% of its 52-week high $173.33 and $276.47. With a market capitalization of about $644.33 billion, Johnson & Johnson is classified as a mega-cap and shows lower-than-market volatility (beta ~0.23). Key stats such as the average daily volume over the past year has been around 7.99 million shares, volume is running light vs its 52-week average. Headquartered in New Brunswick, NJ, Johnson & Johnson operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Joaquin Duato, the company employs approximately 141,700 people and listed since January 02, 1962. Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field.

Johnson & Johnson generated EPS of $11.05 over the past year. Five-year average earnings growth is 14.9%. Wall Street analysts project EPS growth of 8.28% annually over the next five years. The latest quarter delivered EPS of $2.90. The next quarter is forecast at $2.69. Next year's EPS is expected at $7.19. Analyst sentiment is bullish. Analyst rating data shows there are 18 Strong Buy ratings, 19 Buy ratings, 22 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $300.00 to $178.00. The high target offers 9.73% upside. The low target suggests -34.9% downside. The mean target is $237.80. This offers -13.02% upside. Johnson & Johnson earnings surprise history is a consistent trend of beating forecasts. The quarter that ended July 15, 2026, missed forecasts by 2.11%. The prior quarter beat by 0.75%. Over the last six quarters, Apple has recorded several small beats. These include 7.36% in April 15, 2025.

Johnson & Johnson trades at a P/E ratio of 31.13, slightly below the S&P 500 average, with a price-to-sales ratio of 6.63 and a price-to-book ratio of 7.73 trading at moderately above to book value. The P/FCF stands at 34.69, also above market averages.

Johnson & Johnson (NYSE:JNJ) shares are flat 5.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Johnson & Johnson trading at a premium to the broader market with a P/E of 31.13. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $199.69, suggesting -26.96% downside. Our AI forecast model points to short-term strength (0.38% over two weeks), a medium-term rise (9.79% over three months), and a longer-term gain (9.65% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Johnson & Johnson stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.38%, with price expected at $274.45 by September 02, 2026, within a range of $269.16 to $280.06 3-Month Outlook: Projected rise of 9.79%, reaching $300.18 by November 17, 2026, with a range of $295.92 to $304.46. 1-Year Outlook: Projected gain of 9.65%, with price at $299.80 by August 19, 2027, within a range of $293.14 to $309.58.